Table 1 Population characteristics. Placebo (PLA) group and lidocaine (LIDO) group, data as mean ± SD or n (%)
|  | PLA (n = 20) | LIDO (n = 20) |
|---|---|---|
Age (years) | 60 ± 10.9 | 63 ± 12.5 |
Male gender | 10 (50) | 13 (65) |
Weight (kg) | 74 ± 16.5 | 77 ± 14.2 |
BMI (kg/m2) | 26 ± 5.6 | 26 ± 4.9 |
ASA 1 | 1 (5) | 1 (5) |
ASA 2 | 15 (75) | 12 (60) |
ASA 3 | 4 (20) | 7 (35) |
POSSUM (physiologic) | 16.9 ± 3.8 | 19.7 ± 4.1 |
POSSUM (operative) | 12.4 ± 4.5 | 11.4 ± 2.9 |
POSSUM predicted morbidity (%) | 32.4 ± 23.2 | 37.2 ± 18.6 |
POSSUM predicted mortality (%) | 6.4 ± 9.8 | 6.8 ± 6.0 |
Cardiac Risk (LEE criteria) (%) | 1.9 ± 2.4 | 1.4 ± 1.8 |
Comorbidities | ||
 Arterial Hypertension | 9 (45) | 9 (45) |
 Hypercholesterolemia | 4 (20) | 3 (15) |
 Diabetis (typeI or II) | 3 (15) | 5 (25) |
 Ischemic cardiopathy | 3 (15) | 2 (10) |
 Other cardiopathy | 0 | 2 (10) |
 Tobacco abuse | 6 (30) | 6 (30) |
 Renal Insufficiency (KDIGO stage <3b) | 1 (5) | 3 (15) |
 COPD | 3 (15) | 3 (15) |
 Stroke or TIA | 1 (5) | 2 (10) |
 Peripheral Arterial Disease | 1 (5) | 0 |
Medications | ||
 Beta-blockers | 2 (10) | 7 (35) |
 Ca-channel blockers | 2 (10) | 0 |
 ACE - inhibitors | 7 (35) | 4 (20) |
 Nitrates | 0 | 0 |
 Oral Antidiabetic Agents | 1 (5) | 3 (15) |
 Insuline | 2 (10) | 2 (10) |
 Other Medications | 17 (85) | 11 (55) |